These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30253014)

  • 21. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials.
    Blauvelt A; Rosmarin D; Bieber T; Simpson EL; Bagel J; Worm M; Deleuran M; Katoh N; Kawashima M; Shumel B; Chen Z; Rossi AB; Hultsch T; Ardeleanu M
    Br J Dermatol; 2019 Jul; 181(1):196-197. PubMed ID: 30719707
    [No Abstract]   [Full Text] [Related]  

  • 22. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis.
    Bakker DS; van der Wal MM; Heeb LEM; Giovannone B; Asamoah M; Delemarre EM; Drylewicz J; Nierkens S; Boyman O; de Bruin-Weller MS; Thijs JL; van Wijk F
    J Invest Dermatol; 2021 Aug; 141(8):1943-1953.e13. PubMed ID: 33610558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ruxolitinib (Opzelura) for atopic dermatitis.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):12-13. PubMed ID: 35134043
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.
    Quist SR; Ambach A; Göppner D; Quist J; Franke I; Bonnekoh B; Gollnick HP
    Acta Derm Venereol; 2013 Mar; 93(2):206-8. PubMed ID: 23042516
    [No Abstract]   [Full Text] [Related]  

  • 25. Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review.
    Almustafa ZZ; Weller K; Autenrieth J; Maurer M; Metz M
    Acta Derm Venereol; 2019 Sep; 99(10):905-906. PubMed ID: 31233177
    [No Abstract]   [Full Text] [Related]  

  • 26. Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis.
    Ivert LU; Wahlgren CF; Ivert L; Lundqvist M; Bradley M
    Acta Derm Venereol; 2019 Apr; 99(4):375-378. PubMed ID: 30653240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab.
    Collantes-Rodríguez C; Jiménez-Gallo D; Ossorio-García L; Villegas-Romero I; Linares-Barrios M
    Contact Dermatitis; 2019 Jan; 80(1):69-70. PubMed ID: 30334260
    [No Abstract]   [Full Text] [Related]  

  • 28. Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.
    Uchida H; Kamata M; Mizukawa I; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    Br J Dermatol; 2019 Nov; 181(5):1083-1085. PubMed ID: 31127860
    [No Abstract]   [Full Text] [Related]  

  • 29. Inadequate response to ustekinumab in atopic dermatitis - a report of two patients.
    Samorano LP; Hanifin JM; Simpson EL; Leshem YA
    J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):522-3. PubMed ID: 25510643
    [No Abstract]   [Full Text] [Related]  

  • 30. Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis.
    Fowler E; Rosen J; Lev-Tov H; Yosipovitch G
    Acta Derm Venereol; 2019 Sep; 99(10):899-900. PubMed ID: 31037315
    [No Abstract]   [Full Text] [Related]  

  • 31. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.
    Faiz S; Giovannelli J; Podevin C; Jachiet M; Bouaziz JD; Reguiai Z; Nosbaum A; Lasek A; Ferrier le Bouedec MC; Du Thanh A; Raison-Peyron N; Tetart F; Duval-Modeste AB; Misery L; Aubin F; Dompmartin A; Morice C; Droitcourt C; Soria A; Arnault JP; Delaunay J; Mahé E; Richard MA; Schoeffler A; Lacour JP; Begon E; Walter-Lepage A; Dillies AS; Rappelle-Duruy S; Barete S; Bellon N; Bénéton N; Valois A; Barbarot S; Sénéchal J; Staumont-Sallé D;
    J Am Acad Dermatol; 2019 Jul; 81(1):143-151. PubMed ID: 30825533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers.
    He H; Olesen CM; Pavel AB; Clausen ML; Wu J; Estrada Y; Zhang N; Agner T; Guttman-Yassky E
    Front Immunol; 2020; 11():1768. PubMed ID: 32849633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positive Patch Test Reaction in a Patient Taking Dupilumab.
    Puza CJ; Atwater AR
    Dermatitis; 2018; 29(2):89. PubMed ID: 29494389
    [No Abstract]   [Full Text] [Related]  

  • 34. The use of selective Th2 blocker dupilumab for the treatment of atopic dermatitis in a heart transplant patient: Case report.
    Sklover L; Nielson C; De Benedetto A
    Dermatol Ther; 2019 Nov; 32(6):e13144. PubMed ID: 31664753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trial watch: atopic dermatitis therapy breakthrough on the horizon?
    Cully M
    Nat Rev Drug Discov; 2014 Sep; 13(9):645. PubMed ID: 25176425
    [No Abstract]   [Full Text] [Related]  

  • 36. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial.
    Tsianakas A; Luger TA; Radin A
    Br J Dermatol; 2018 Feb; 178(2):406-414. PubMed ID: 28845523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
    Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
    J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dupilumab for Atopic Dermatitis, a Possible Risk Factor of Juvenile Ischemic Stroke: A Case Report.
    Iwase R; Ishiguro T; Fujita K; Ishibashi S; Yokota T
    J Stroke Cerebrovasc Dis; 2020 Jun; 29(6):104763. PubMed ID: 32265139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials.
    Fleming P; Drucker AM
    J Am Acad Dermatol; 2018 Jan; 78(1):62-69.e1. PubMed ID: 28987493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful Treatment with Dupilumab in a Patient with Severe, Difficult to Treat Atopic Dermatitis: Beware of Symptomatic Adrenal Insufficiency due to Abrupt Discontinuation of Potent Topical Corticosteroids.
    Ariëns LFM; van der Schaft J; Stades AME; van de Woestijne AA; De Bruin-Weller MS
    Acta Derm Venereol; 2018 Jun; 98(6):601-602. PubMed ID: 29881868
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.